Pharmaceutical conferences differ from every other sector covered in this series, because the interaction itself is regulated, not just the data it produces.
At an industrial fair the compliance question is "may I record this conversation." At a pharma congress it is that, plus: what may be said, to whom, whether anything of value changed hands, and what must be disclosed afterwards.
Not legal or regulatory advice. Pharma promotional compliance is jurisdiction-specific and organisation-specific. Involve medical, legal and compliance affairs before changing any capture process.
The interaction is the regulated object
Three overlapping regimes typically apply.
Transparency reporting. In the US, the Physician Payments Sunshine Act requires applicable manufacturers to report transfers of value to physicians and teaching hospitals. In Europe, the EFPIA Disclosure Code and national implementations impose comparable obligations. A meal, a travel contribution or hospitality at a congress can constitute a reportable transfer of value — arising from a booth interaction that produced no sale at all.
Promotional rules. What may be said about a medicine to a healthcare professional is tightly constrained. Off-label discussion, unapproved claims and unsolicited promotional communication are all regulated, with rules differing by market.
Scientific exchange boundaries. Many pharma organisations draw a firm line between commercial staff and medical affairs, precisely because the permitted conversation differs.
None of this is a reason to avoid capturing leads. It is a reason for the capture process to record compliance-relevant facts, not only commercial ones.
What a pharma event record should contain
- Professional role and specialty — determines what may be discussed
- Institution and type — teaching hospital status matters for US reporting
- Interaction type — scientific exchange, promotional, unsolicited enquiry
- Transfer of value — did anything reportable occur
- Solicited or unsolicited — critical for off-label enquiry handling
- Materials provided — which approved materials were given
- Follow-up owner — commercial or medical affairs
In many pharma organisations, the second half of that list matters more than the first.
The unsolicited-enquiry rule
One pattern worth designing for explicitly.
If a healthcare professional spontaneously asks about an unapproved indication, most regulatory frameworks permit a response through medical information channels — but the enquiry must be documented as unsolicited, and the response must come from the appropriate function.
That means the capture process needs a way to record that the question was asked and by whom it was initiated. A generic lead form has no such field, and a rep improvising the answer at a booth is a compliance incident.
Brief booth staff explicitly:
- If asked about anything off-label, do not answer
- Route to medical information
- Record that the enquiry was unsolicited
Recording: proceed carefully
Recording rules follow the venue's jurisdiction — the same country-by-country analysis as any other event, covered in our guide to recording consent at trade shows.
Pharma adds two sector-specific cautions.
Patient information. Clinicians frequently illustrate requirements with real cases. That risks capturing patient-identifiable information, which in the US may engage HIPAA and in Europe engages GDPR's special-category rules under Article 9.
Durable records of promotional conversations. A recording is evidence. If a rep says something that strays outside approved claims, that is now documented. Compliance teams have legitimate views on this, and they should be consulted before deployment rather than after.
The practical resolution most pharma organisations reach is: capture structured facts rather than retaining raw audio, with clear staff briefing on what to do when a conversation moves toward patients or off-label topics.
Extract-then-delete is the right architecture here for compliance reasons as much as data-protection ones. It is how Confee is built — the conversation becomes structured fields and the audio need not be retained.
The pharma capture checklist
Before the congress
- Compliance and medical affairs have reviewed the capture process
- Fields exist for interaction type and transfer of value
- Booth staff briefed on the off-label boundary and the routing rule
- Approved materials list confirmed
- Consent script prepared for the venue's jurisdiction
Per interaction
- Record role, specialty and institution type
- Classify the interaction — scientific, promotional, unsolicited
- Note any transfer of value
- Stop recording if a specific patient is described
- Route off-label enquiries to medical information
After
- Feed transfer-of-value data into the transparency reporting process
- Route medical enquiries to the correct function within required timeframes
- Retain compliance records per policy — usually longer than commercial records
The short version
Pharma lead capture is a compliance process that also produces sales leads. Capture role, institution type, interaction classification and any transfer of value. Brief staff on the off-label boundary before the doors open.
And involve compliance before deploying any recording — not after.
Related reading:
- Lead Capture for Medtech Trade Shows — the adjacent regulated sector
- Is Recording Sales Conversations Legal? — jurisdiction-by-jurisdiction
- GDPR-Compliant Lead Capture — special-category data considerations
FAQ
What makes lead capture at pharma conferences different?
Compliance obligations attach to the interaction itself. Interactions with healthcare professionals may trigger transparency reporting under the Sunshine Act or EFPIA Disclosure Code, and promotional communication is tightly regulated.
Can you record conversations with healthcare professionals at a pharma event?
Recording rules follow the venue's jurisdiction, but pharma adds caution. Conversations touching patient cases, off-label topics or promotional claims create durable records compliance will want reviewed. Involve medical and legal affairs first.
What is the Sunshine Act and does it affect trade show interactions?
It requires applicable US manufacturers to report transfers of value to physicians and teaching hospitals. Meals, travel or gifts at a conference can be reportable, so booth interactions may generate obligations independent of any sale.
What should pharma exhibitors capture at events?
Professional role and specialty, institution and type, interaction nature (scientific versus promotional), whether a transfer of value occurred, whether the discussion was unsolicited, and the agreed follow-up.